Clinical trial
Assessment of Liver Glucose Metabolism in Diabetic Subjects
Name
CLAVA
Description
Type 2 diabetes is associated with hepatic insulin resistance. One consequence of insulin resistance of the liver is an altered hepatic glucose metabolism. This study investigates whether the whole body (M-value) and hepatic insulin sensitivity obtained by hyperinsulinemic euglycemic clamp is influenced by a preceding intravenous glucose tolerance test (Botnia Clamp) in subjects with type 2 diabetes.
Trial arms
Trial start
2011-07-01
Estimated PCD
2013-12-01
Trial end
2013-12-01
Status
Completed
Treatment
intravenous glucose tolerance test
Administration of a 30% weight-adapted glucose bolus intravenously.
Arms:
Botnia clamp
Other names:
ivGTT
hyperinsulinemic euglycemic clamp
Intravenous administration of 20% glucose and insulin over 3 hours
Arms:
Botnia clamp, hyperinsulinemic euglycemic clamp
Other names:
HEC
Size
22
Primary endpoint
M Value in hyperinsulinemic euglycemic clamp
3h
Eligibility criteria
Inclusion Criteria:
* newly diagnosed type 2 diabetes (during the last 12 months)or non-diabetic subjects
Exclusion Criteria:
* severe chronic diseases
* hepatitis B, C oder HIV infection
* malignancies
* immune suppressive therapy
* psychiatric illnesses
* drug or alcohol abuse
* anemia
* renal dysfunction
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'CROSSOVER', 'primaryPurpose': 'BASIC_SCIENCE', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 22, 'type': 'ACTUAL'}}
Updated at
2023-06-05
1 organization
2 products
1 indication
Organization
German Diabetes CenterIndication
Type 2 Diabetes